SURVYR

DNA

DNA
$11.27
+$1.25 (12.48%)Oct 27 close
US Equities CompareTechnicals
-59%-41%-22%-4%+15%Oct 2025Oct 2026Apr 202652w high $14.9852w low $5.48
DNASPY
Wall St. Highest PT $19.01 (+68.7%) Wall St. Avg PT $15.58 (+38.2%)
$5$9$13$16$20POC $9Hi $19Avg $16
Underwater Drawdown %Max DD -59.1%Current -24.8%
0.0%-59.1%
Relative Strength vs SPY-29.4% vs SPYUnderperforming
+74%0%-74%
1W
+$1.41 (14.30%)
1M
+$0.61 (5.72%)
3M
+$3.57 (46.36%)
6M
+$3.42 (43.57%)
YTD
+$2.96 (35.62%)
1Y
−$2.12 (15.83%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for DNA
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$5.48 – $14.98

What they do

Ginkgo Bioworks Holdings, Inc. develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for DNA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
SURVYR. Long Book
Not in the current book

Earnings & events

DNA earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Time not confirmed
EPS consensus-$0.54
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.73est -$0.70−4.7%Below estimates
May 7, 2026-$1.39est -$1.34−3.7%Below estimates
Feb 26, 2026-$0.77est -$1.11+30.5%Above estimates
Nov 6, 2025-$1.45est -$1.24−16.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 18:09:15 ET
24-1125-0225-0525-0825-1126-0226-0526-08-3.320.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Kelly Jason R
Director, See remarks · 2026-10-19
Sell
$463.4K
Shetty Reshma P.
Director, See remarks, 10% owner · 2026-10-19
Sell
$190.7K
Shetty Reshma P.
Director, See remarks, 10% owner · 2026-10-19
Sell
$226.9K
Canton Barry
10% owner · 2026-10-19
Sell
$226.9K
Canton Barry
10% owner · 2026-10-19
Sell
$190.7K
Coen Steven P.
See remarks · 2026-10-19
Sell
$7.8K
Coen Steven P.
See remarks · 2026-10-05
Sell
$36.0K
Henry Christian O
Director · 2026-09-15
Sell
$35.4K
Coen Steven P.
See remarks · 2026-08-24
Sell
$2.3K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:09:15 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Coteau 0.9 · Oct 21, 2026